|
Health Condition(s) or Problem
|
Lymphoma; Neurotoxicity
|
|
Lay Summary
|
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. It is not yet known
which regimen of combination chemotherapy is more effective for Hodgkin lymphoma.
PURPOSE: This phase II trial is studying the side effects of three different regimens of
combination chemotherapy and to see how well they work in treating younger patients with
Hodgkin lymphoma.
(from ClinicalTrials.gov)
|
|
Who can enter the trial
|
DISEASE CHARACTERISTICS:
- Biopsy proven de-novo classical Hodgkin lymphoma
- Any stage disease
- No nodular lymphocyte-predominant Hodgkin lymphoma
PATIENT CHARACTERISTICS:
- No known or suspected HIV infection
- No pre-existing neurological disorder
- No serious comorbidity which may prevent administration of study treatment
- No other previous malignancy
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for up to 1 year after
completion of study treatment
- Creatinine = 1.5 times upper limit of normal (ULN) unless due to the lymphoma
- ALT/AST = 1.5 times ULN unless due to the lymphoma
- Bilirubin = 2 times ULN unless due to the lymphoma
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy
- No prior organ transplant
|
|
Who cannot enter the trial
|
DISEASE CHARACTERISTICS:
- Biopsy proven de-novo classical Hodgkin lymphoma
- Any stage disease
- No nodular lymphocyte-predominant Hodgkin lymphoma
PATIENT CHARACTERISTICS:
- No known or suspected HIV infection
- No pre-existing neurological disorder
- No serious comorbidity which may prevent administration of study treatment
- No other previous malignancy
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for up to 1 year after
completion of study treatment
- Creatinine = 1.5 times upper limit of normal (ULN) unless due to the lymphoma
- ALT/AST = 1.5 times ULN unless due to the lymphoma
- Bilirubin = 2 times ULN unless due to the lymphoma
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy
- No prior organ transplant
|
|
What will happen
|
Drug; cyclophosphamide; Drug; doxorubicin hydrochloride; Drug; etoposide; Drug; prednisolone; Drug; procarbazine hydrochloride; Drug; vincristine sulfate; Radiation; radiation therapy
|
|
Primary aim
|
Neurotoxicity due to the intensive use of Vinca alkaloids
|
|
Secondary Aim
|
Response rate; No; Disease-free survival; No; Overall survival; No; Gonadal toxicity; Yes
|
|
Participant Information Sheet
|
Sorry, not currently available
|
|
Website
|
Sorry, not currently available
|
|
Recruitment Status
|
Recruiting
|
|
Nation
|
England
|
|
Location
|
Leeds, London, Newcastle upon Tyne, Northwood
|